Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective;Neumonía nosocomial causada por Staphylococcus aureus resistente a meticilina tratada con linezolid o vancomicina: análisis económico secundario del uso de recursos sanitarios desde una perspectiva española

Medicina Intensiva

Volumn 40, Issue 8, 2016, Pages 474-482

  Rello, J ^a   Nieto, M ^b   Sole Violan J ^c   Wan, Y ^d   Gao, X ^d   Solem, C T ^d   De Salas Cansado, M ^e   Mesa, F ^e   Charbonneau, C ^e   Chastre, J ^f  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d PHARMERIT INTERNATIONAL   (United States)

^e PFIZER INC   (United States)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Economics; Methicillin resistant Staphylococcus aureus; Pneumonia; Renal failure; Spain

Indexed keywords

LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; METICILLIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ACQUIRED PNEUMONIA; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SPAIN; VERY ELDERLY; CROSS INFECTION; DOUBLE BLIND PROCEDURE; ECONOMICS; HEALTH CARE COST; STAPHYLOCOCCAL PNEUMONIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DOUBLE-BLIND METHOD; HEALTH CARE COSTS; HUMANS; LINEZOLID; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, STAPHYLOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84962469707     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2016.01.007     Document Type: Article

References (22)

1. 1 Jones, R.N., Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51 (2010), S81–S87.
2. 2 Ayliffe, G.A., The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 24 (1997), S74–S79.
3. 3 Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52 (2011), 285–292.
4. 4 Zyvox [package insert]. 2012, Pharmacia and Upjohn Company, Division of Pfizer, Inc., New York, NY.
5. 5 Nosocomial pneumonia with suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) (ZEPHyR). ClinilcaTrials.gov, 2004, National Library of Medicine (US), Bethesda, MD Available from http://clinicaltrials.gov/show/NCT00084266. Identification No. NCT00084266 [cited 2012].
6. 6 Wunderink, R.G., Niederman, M.S., Kollef, M.H., Shorr, A.F., Kunkel, M.J., Baruch, A., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54 (2012), 621–629.
7. 7 European Centre for Disease Prevention and Control (ECDC), Antimicrobial resistance surveillance in Europe. 2012 Available at: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf [accessed 30.10.14].
8. 8 Vincent, J.L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., et al. International study of the prevalence and outcomes of infection in intensive care units. J Am Med Assoc 302 (2009), 2323–2329.
9. 9 Cosgrove, S.E., The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 (2006), S82–S89.
10. 10 León, C., Gómez Mateos, J., Catalá, R., Vázquez, M., Alvarez Rocha, L., Nájera, M., et al. PIN14 cost-effectiveness of linezolid versus vancomycin in the treatment of nosocomial pneumonia suspected to be caused by methicillin-resistant Staphylococcus aureus in Spain. Value Health 10 (2007), A439–A440.
11. 11 Niederman, M.S., Chastre, J., Solem, C.T., Wan, Y., Gao, X., Myers, D.E., et al. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid. Clin Ther 36 (2014), 1233–1243.
12. 12 Mehta, R.L., Kellum, J.A., Shah, S.V., Molitoris, B.A., Ronco, C., Warnock, D.G., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care, 11, 2007, R31.
13. 13 General Council of Official Colleges of Pharmacists. Bot PLUS 2.0. https://botplusweb.portalfarma.com [accessed 15.03.13].
14. 14 Oblikue Consulting Health. Información económica del sector sanitaria. http://www.oblikue.com/bddcostes [accessed 15.03.13].
15. 15 Wan, Y., Li, Q., Chen, Y., Haider, S., Liu, S., Gao, X., Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study. J Med Econ 19 (2016), 53–62.
16. 16 Rico, A., Sabes, R., Wisbaum, W., Health care systems in transition: Spain. 2000, WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies, Copenhagen.
17. 17 Blumenthal, D., Hsiao, W., Privatization and its discontents—the evolving Chinese health care system. N Engl J Med 353 (2005), 1165–1170.
18. 18 Anderson, G.F., Squires, D.A., Measuring the US health care system: a cross-national comparison. Issue Brief (Commonw Fund) 90 (2010), 1–10.
19. 19 Patel, D.A., Shorr, A.F., Chastre, J., Niederman, M., Simor, A., Stephens, J.M., et al. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Crit Care, 18, 2014, R157.
20. 20 Patel, D.A., Michel, A., Stephens, J., Weber, B., Petrik, C., Charbonneau, C., An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infect Drug Resist 7 (2014), 273–280.
21. 21 Rubio-Terrés, C., Garau, J., Grau, S., Martinez-Martinez, L., Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect 16 (2010), 722–728.
22. 22 Rello, J., Lisboa, T., Koulenti, D., Mañez, R., Martin-Loeches, I., De Waele, J., et al. Determinants of choice and prescription patterns in empiric antibiotic therapy for HAP/VAP. Eur Respir J 37 (2011), 1332–1339.